Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says
The FDA is allowing Regenxbio to resubmit its gene therapy for Hunter syndrome, marking a reversal of a previous rejection.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Regenxbio has been granted a path to resubmit its gene therapy, known as NAVSUNLI, for the treatment of Hunter syndrome (MPS II). This follows a previous rejection by the FDA regarding the childhood treatment.
Coverage from the Wall Street Journal, Endpoints News, Stat News, Stock Titan, and Seeking Alpha highlights the regulatory shift. Reports emphasize that this marks a broader trend of the FDA reconsidering previous decisions for rare-disease drugs.
Regenxbio is expected to move forward with the resubmission process for the drug. Market observers note that the company faces heightened pressure to deliver results regarding its wider pipeline, including ongoing work in Duchenne muscular dystrophy.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 58d ago.
Quick answers
What is the status of the Hunter syndrome gene therapy?
The FDA has granted Regenxbio permission to resubmit its application for NAVSUNLI following a prior rejection.
Which condition is the therapy intended to treat?
The therapy is intended for Hunter syndrome, also referred to as MPS II.
What other conditions is Regenxbio researching?
Coverage indicates the company is also working on treatments for Duchenne muscular dystrophy.
Coverage (12)
- REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II Yahoo Finance · 58d ago
- FDA reconsiders rejected rare-disease gene therapy Baton Rouge Business Report · 58d ago
- US FDA reverses course on Regenxbio's rare-disease gene therapy, backs accelerated approval bid Reuters · 58d ago
- REGENXBIO to resubmit application for Hunter gene therapy after FDA’s most recent pivot BioSpace · 58d ago
- In another reversal for rare disease field, FDA to reconsider Regenxbio gene therapy Fierce Biotech · 58d ago
- Reuters US Domestic News Summary Devdiscourse · 58d ago
- US FDA Reverses Course on Regenxbio's Rare-Disease Gene Therapy, Backs Accelerated Approval Bid U.S. News & World Report · 58d ago
- Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues Endpoints News · 58d ago
- REGENXBIO gets FDA path to resubmit NAVSUNLI for MPS II Stock Titan · 58d ago
- REGENXBIO’s Duchenne Data Keeps Me Bullish, But There’s Less Room For Setbacks Now (RGNX) Seeking Alpha · 58d ago
- FDA reverses course on Regenxbio’s childhood gene therapy after rejection statnews.com · 58d ago
- Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says WSJ · 58d ago
Topics
Related trends
Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T
Exclusive reporting reveals a third death in China's opaque gene therapy trials, sparking intense scrutiny of safety oversight.
FDA puts Texas egg recall in highest-risk category. What to know - Austin American-Statesman
The FDA has designated a Texas egg recall as Class I, the highest risk category, due to Salmonella contamination.
FDA heightens egg recall to reflect potential ‘serious adverse health consequences or death’
The FDA has issued its highest-level safety alert to recall 19 million eggs due to a salmonella outbreak posing risks of serious illness or death.
FDA upgrades egg recall to highest health-risk level amid string of food safety concerns
The FDA has escalated a massive egg recall to its highest health-risk category following potential Salmonella Enteritidis contamination.
Will Autonomous AI Exceed AI-Aided Physicians as the Best Medical Care?
A debate is intensifying over whether autonomous AI will eventually surpass AI-aided physicians as the primary provider of high-quality medical care.
Whoop stood up to the FDA and helped make the Pixel Watch 5’s blood pressure feature possible
Whoop's regulatory challenges with the FDA have paved the way for the blood pressure monitoring capabilities found in the new Pixel Watch 5.